Cours suspendu

Communiqués MORC HOLD

Actions

MORF

US61775R1059

Marché Fermé - Nasdaq 22:00:00 15/08/2024			Varia. 5j.	Varia. 1 janv.
56,99 ^USD	+0,04%		-.--%	-

16/08/24	Eli Lilly finalise l'achat du groupe biopharmaceutique Morphic	MT
16/08/24	Eli Lilly finalise l'acquisition de Morphic Holding pour 3,2 milliards de dollars	MT

Communiqués

16/08/24	Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease	PR
31/07/24	MORF Alert: Wohl & Fruchter LLP Files Class Action Lawsuit on Behalf of Shareholders of Morphic Holding, Inc., in the U.S. District Court for the Northern District of California	AQ
19/07/24	MORPHIC HOLDING INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Morphic Holding, Inc. - MORF	BU
09/07/24	MORPHIC HOLDING INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Morphic Holding, Inc. - MORF	BU
08/07/24	MORF Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Morphic Holding to Eli Lilly	AQ
08/07/24	Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease	PR
31/05/24	Morphic to Participate in Jefferies Global Healthcare Conference	AQ
21/05/24	Morphic : DDW 2024 A4B7 Inhibition IVM Poster	PU
21/05/24	Morphic Demonstrates Novel Real-Time Visualization of Small Molecule α4β7 Inhibition of Gut-Trafficking Cells	AQ
09/05/24	Morphic to Participate in RBC Capital Markets Global Healthcare Conference	AQ
25/04/24	Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024	AQ
03/04/24	Ademi LLP Investigates Claims of Securities Fraud against Morphic Holding, Inc.	PR
19/03/24	Morphic Appoints Dr. Simon Cooper as Chief Medical Officer	AQ
05/03/24	Morphic to Participate in March Investor Conferences	AQ
22/02/24	Morphic Announces Corporate Highlights and Financial Results for the Full Year 2023	AQ
03/01/24	Morphic to Present at the 42nd Annual J.P. Morgan Healthcare Conference	AQ
10/11/23	Morphic to Present at November Investor Conferences	AQ
03/11/23	Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023	AQ
21/10/23	Morphic Holding Investigation: Johnson Fistel Encourages Shareholders with Losses to Contact the Firm Regarding Investigation	BU
14/10/23	Morphic Holding Johnson Fistel Encourages Morphic Holding Shareholders with Losses to Contact the Firm Regarding Investigation	BU
09/10/23	Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set	AQ
29/09/23	MORF INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Morphic Holding, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm	BU
26/09/23	Morphic Holdings Announces CEO Dr. Praveen Tipirneni to Take Temporary Medical Leave of Absence	AQ
22/09/23	Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023	AQ
29/08/23	Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference	AQ